A5057152129- Hematopoietic Stem Cell Transplantation
- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Mesenchymal stem cell research
- Systemic Sclerosis and Related Diseases
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- CAR-T cell therapy research
- Autoimmune and Inflammatory Disorders Research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Erythropoietin and Anemia Treatment
- Immunotherapy and Immune Responses
- Transplantation: Methods and Outcomes
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Hemoglobinopathies and Related Disorders
- Neurogenesis and neuroplasticity mechanisms
- Pancreatic function and diabetes
- Chronic Lymphocytic Leukemia Research
- Periodontal Regeneration and Treatments
- Tissue Engineering and Regenerative Medicine
- Immunodeficiency and Autoimmune Disorders
Azienda Ospedaliero-Universitaria Careggi
2016-2025
University of Florence
2008-2022
Gruppo Italiano per il Trapianto di Midollo Osseo
1994-2020
John Wiley & Sons (United States)
2020
Hudson Institute
2020
Meyer Children's Hospital
2020
Ospedale Policlinico San Martino
2017
University of Genoa
2017
Martin University
2017
Imperial College London
2017
High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have shown efficacy in systemic sclerosis phase 1 small 2 trials.To compare safety of HSCT vs 12 successive monthly intravenous pulses cyclophosphamide.The Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a 3, multicenter, randomized (1:1), open-label, parallel-group, clinical trial conducted 10 countries at 29 centers with access to European Group for Blood Marrow...
Background Autologous hematopoietic stem cell transplantation has been used since 1996 for the treatment of severe autoimmune diseases refractory to approved therapies. We evaluated long-term outcomes these transplants and aimed identify potential prognostic factors.Design Methods In this observational study we analyzed all first autologous reported European Group Blood Marrow Transplantation (EBMT) registry between 1996–2007. The primary end-points analysis were overall survival,...
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic engineered to express CAR targeting membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment refractory/relapsed acute lymphoblastic leukemia children and young adults as well relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta™) high-grade lymphoma primary mediastinal lymphoma. Both agents genetically CD19....
Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade lymphoma mantle cell lymphoma. Products other diseases such as multiple myeloma follicular are likely to be by the European Medicines Agency near future.The Society Blood Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT EBMT (JACIE) Haematology Association...
Autologous hematopoietic stem cell transplantation (AHSCT) may be effective in aggressive forms of multiple sclerosis (MS) that fail to respond standard therapies.To evaluate the long-term outcomes patients who underwent AHSCT for treatment MS a large multicenter cohort.Data were obtained multicenter, observational, retrospective cohort study. Eligibility criteria receipt between January 1995 and December 2006 availability prespecified minimum data set comprising disease subtype at baseline;...
<h3>Objective:</h3> To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured MRI. <h3>Methods:</h3> We conducted a multicenter, phase II, randomized trial including patients with secondary progressive or relapsing-remitting MS, documented increase last year Expanded Disability Status Scale, spite conventional therapy, and presence one more...
These updated EBMT guidelines review the clinical evidence, registry activity and mechanisms of action haematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) other immune-mediated neurological diseases provide recommendations for patient selection, transplant technique, follow-up future development. The major focus is on autologous HSCT (aHSCT), used MS over two decades currently fastest growing indication this treatment Europe, with increasing evidence to support its use...
Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require repeated administration. Recently, novel cellular (CT), including mesenchymal stromal cells (MSC), Chimeric Antigen Receptors T (CART) regulatory (Tregs), have been successfully adopted in ADs. An international expert panel the European Society for...
Over the last decade, hematopoietic stem cells transplantation (HSCT) has been increasingly used in treatment of severe progressive autoimmune diseases. We report a retrospective survey 183 multiple sclerosis (MS) patients, recorded database European Blood and Marrow Transplantation Group (EBMT). Transplant data were available from 178 patients who received an autologous graft. Overall, transplant related mortality (TRM) was 5.3% restricted to period 1995-2000, with no further TRM reported...
Systemic lupus erythematosus (SLE) is responsive to treatment with immunosuppressives and steroids, but often pursues a relapsing or refractory course resulting in increasing incapacity reduced survival. Autologous stem cell transplantation (ASCT) following immunoablative chemotherapy newer therapy for autoimmune disease of potential use severe SLE. A retrospective registry survey was carried out by the European Blood Marrow Transplant League Against Rheumatism (EBMT/EULAR) registry. Data...
<h3>Importance</h3> Case reports and series suggest hematopoietic stem cell transplantation (HSCT) may benefit some patients with Crohn disease. <h3>Objective</h3> To evaluate the effect of autologous HSCT on refractory <h3>Design, Setting, Participants</h3> Parallel-group randomized clinical trial conducted in 11 European transplant units from July 2007 to September 2011, follow-up through March 2013. Patients were aged 18 50 years impaired quality life disease not amenable surgery despite...
Abstract Objective Systemic sclerosis (SSc) is a disorder characterized by vascular damage and fibrosis of the skin internal organs. Despite marked tissue hypoxia, there no evidence compensatory angiogenesis. The ability mesenchymal stem cells (MSCs) to differentiate into endothelial was recently demonstrated. aim this study determine whether impaired differentiation MSCs in SSc might contribute disease pathogenesis decreasing repair. Methods obtained from 7 patients 15 healthy controls were...
Background: Over recent years numerous patients with severe forms of multiple sclerosis (MS) refractory to conventional therapies have been treated intense immunosuppression followed by autologous haematopoietic stem cell transplantation (AHSCT). The clinical outcome and the toxicity AHSCT can be diverse, depending on various types conditioning protocols disease phase. Objectives: To report Italian experience all consecutive MS an intermediate intensity regimen, named BEAM/ATG, in period...
Mesenchymal stromal cells (MSCs) are the leading cell candidates in field of regenerative medicine. These have also been successfully used to improve skeletal muscle repair/regeneration; however, mechanisms responsible for their beneficial effects remain be clarified. On this basis, present study, we evaluated a co-culture system, ability bone-marrow MSCs influence C2C12 myoblast behavior and analyzed cross-talk between two types at cellular molecular level. We found that proliferation was...